Based on recent research and analysis of the Chinese cell therapy drug market, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) awarded the 'China Cell Drug Innovation Award' to Shihuli Biotechnology Co., Ltd. (hereinafter referred to as 'Shihuli Biotech'), with Dr. Xin Wang, a global partner at Frost & Sullivan and Chairman of Greater China, presenting the award to Dr. Yarong Liu, the founder of Shihuli Biotech.
Frost & Sullivan awarded Shihuli Biotechnology Co., Ltd.
the 'China Cell Drug Innovation Award'
Dr. Xin Wang presented the award to Dr. Yarong Liu, the founder of Shihuli Biotech
Shihuli Biotech is a leading domestic biopharmaceutical company represented by TIL cell therapy
Founded in 2019, Shihuli Biotech is a leading domestic company focusing on tumor immune cell therapy, represented by tumor-infiltrating lymphocytes (TIL) therapy. TIL therapy is a type of cell drug and is considered to have great innovative therapeutic potential in the field of solid tumor treatment. The company has multiple core technologies in TIL cell screening, amplification, and genetic engineering, which can be applied to the development of next-generation solid tumor TIL therapy.
Promoting TIL therapy into clinical practice, bringing new treatment prospects to Chinese solid tumor patients
Shihuli Biotech's independently developed and produced TIL therapy treatment product GT101 injection officially obtained a clinical trial implied approval from the National Medical Products Administration in April 2022, becoming China's first TIL therapy product to enter clinical trials, and is currently about to enter the critical phase II clinical trial stage. On July 12, 2023, Shihuli Biotech's independently developed next-generation gene-edited TIL product GT201 injection, expressing membrane-bound cytokines, officially obtained a clinical trial implied approval from the National Medical Products Administration and entered the clinical stage. These innovative breakthroughs are expected to bring new treatment options to solid tumor patients.
Multiple core technologies, creating cancer treatment technologies with higher safety and better therapeutic effects
Shihuli Biotech's TIL cell therapy technology relies on its own core R&D technology platform and has core advantages in TIL cell amplification, transfection, target screening, and gene knockout. Research data shows that the next-generation TIL therapy developed based on its core platform has stronger proliferation ability, better tumor-killing ability and cytokine release ability, as well as better persistence compared to traditional TIL therapy, effectively addressing the challenges faced by traditional TIL therapy. Shihuli Biotech's TIL cell therapy has shown good therapeutic potential in clinical trials targeting various advanced solid tumors and is expected to become a pioneering treatment product in the field of solid tumor cell drugs, bringing new treatment hope to cancer patients.
About the Frost & Sullivan Life Sciences New Investment Summit Forum
The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27-28, with the theme 'New Directions for the Future, Forge Ahead', bringing together more than 30 industry leaders, life science companies, investment institutions, and professional service providers. It focused on new opportunities for life sciences investment and financing, jointly discussing the capital and industrial forces for enterprises to navigate through cycles.
About the Frost & Sullivan China Innovation Award
The Frost & Sullivan China Innovation Award recognizes outstanding performance and achievements of enterprises in technological innovation, market potential, customer service, brand, etc. The Frost & Sullivan team nominated a group of competitive and excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and well-known listed entrepreneurs conducted a strict review of the enterprises nominated by the Frost & Sullivan team and decided to award the 'China Cell Drug Innovation Award' to Shihuli Biotechnology Co., Ltd.
